Alphabet, GeneScience, AstraZeneca, Shire, Novartis, Ping An, KPC and Stevanato are in line for exits after the drug delivery technology developer filed to go public.

The Boston Scientific-backed medical device maker has filed to raise up to $100m in an offering on the Nasdaq Global Market.

The GV-backed heart disease treatment developer intends to go public this year having secured $248m in venture funding.

The Tencent, China Electronics Corporation, Sinopharm and Sunshine Insurance-backed healthcare efficiency software provider raised $77.2m in the round.

Corporate partnership CR-CP Life Science Fund led the cancer detection test developer’s series C round, which took its total funding to $120m.

Munich Re and Microsoft helped CO2-to-chemicals technology provider Twelve raise $57m while Eli Lilly and Kaiser Permanente-backed CRO dMed-Clinipac secured $50m.

The precision oncology platform is based on research by Duke and Hubrecht Institute faculty and the cash will fund technology development and clinical studies.

The Alibaba-backed medical data software provider has reportedly halted plans for a $211m offering due to regulatory concerns.

The fund will invest in companies linked to École Polytechnique, including spinouts, alumni-founded startups or businesses incubated by the school.

Medison has contributed to a private placement in support of portfolio company Alpha Tau Medical’s $1bn reverse merger with Healthcare Capital Corp.